China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

The Centre for DNA Fingerprinting and Diagnostics Hyderabad invites online applications for Scientist-III and Scientist-IV ...

ATLATL, one of China’s leading biotech incubators, is seeking to bridge East-West innovation and tap into China's rapidly ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

Bengaluru's Pandorum Technologies teams up with Nucelion Therapeutics to scale its exosome-based therapeutic platform across ...

It’s the latest move in the race by drug companies to corner more of the highly-lucrative obesity drug market.

With major NIH cuts under Trump, here are initiatives in states like New York, California and Massachusetts to get state ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

The Molecular Biology Research Group under the Biotechnology and Genetic Engineering department of Islamic University (IU) in ...

He emphasised collaboration between startups and research labs and the need for hands-on experience in AI, quantum computing ...